Consider This Before Taking a Position in Linde (LIN)

By Susan Ramirez • Thursday, November 16 12:20 • Permanent Link

Join us for a quick overview of Linde, a Chemicals company whose shares moved -0.7% today. Here are some facts about the stock that should help you see the bigger picture:

Linde has moved 22.0% over the last year, and the S&P 500 logged a change of 15.0%
LIN has an average analyst rating of buy and is -6.14% away from its mean target price of $425.98 per share
Its trailing earnings per share (EPS) is $12.08
Linde has a trailing 12 month Price to Earnings (P/E) ratio of 33.1 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $15.43 and its forward P/E ratio is 25.9
The company has a Price to Book (P/B) ratio of 4.98 in contrast to the S&P 500's average ratio of 2.95
Linde is part of the Industrials sector, which has an average P/E ratio of 20.49 and an average P/B of 3.78
LIN has reported YOY quarterly earnings growth of 25.6% and gross profit margins of 0.5%
The company has a free cash flow of $3.83 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Linde plc operates as an industrial gas company in North and South America, Europe, the Middle East, Africa, and the Asia Pacific. It offers atmospheric gases, including oxygen, nitrogen, argon, and rare gases; and process gases, such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene. The company also designs and constructs turnkey process plants for third-party customers, as well as for the gas businesses in various locations, such as air separation, hydrogen, synthesis, olefin, and natural gas plants. It serves a range of industries, including healthcare, chemicals and energy, manufacturing, metals and mining, food and beverage, and electronics. The company was founded in 1879 and is based in Woking, the United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.